Pancreatic ductal
adenocarcinoma is an aggressive cancer that interacts with stromal cells to
produce a highly inflammatory tumor microenvironment that promotes tumor growth
and invasiveness. The precise interplay between tumor and stroma remains poorly
understood. TLRs mediate interactions between environmental stimuli and innate
immunity and trigger proinflammatory signaling cascades. Our finding that TLR7
expression is upregulated in both epithelial and stromal compartments in human
and murine pancreatic cancer led us to postulate that carcinogenesis is
dependent on TLR7 signaling. In a mouse model of pancreatic cancer, TLR7 ligation
vigorously accelerated tumor progression and induced loss of expression of
PTEN, p16, and cyclin D1 and upregulation of p21, p27, p53, c-Myc, SHPTP1,
TGF-β, PPARγ, and cyclin B1. Furthermore, TLR7 ligation induced STAT3
activation and interfaced with Notch as well as canonical NF-κB and MAP kinase
pathways, but downregulated expression of Notch target genes. Moreover,
blockade of TLR7 protected against carcinogenesis. Since pancreatic
tumorigenesis requires stromal expansion, we proposed that TLR7 ligation
modulates pancreatic cancer by driving stromal inflammation. Accordingly, we
found that mice lacking TLR7 exclusively within their inflammatory cells were
protected from neoplasia. These data suggest that targeting TLR7 holds promise
for treatment of human pancreatic cancer.
Source: Toll-like
receptor 7 regulates pancreatic carcinogenesis in mice and humans. Ochi A,
Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning
JR, Jamal M, Rao R, Greco S, Deutsch M, Medina-Zea MV, Saeed UB, Ego-Osuala MO,
Hajdu C, Miller G (george.miller@nyumc.org).
J Clin Invest. 2012 Oct 1. pii: 63606.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire